

Environmental and Social Data Sheet

Overview

Project Name: EVAXION
Project Number: 2019-0227
Country: Denmark
Project Description: The Project supports the development of a platform for drug discovery exploiting Artificial Intelligence (AI), as well as the build-up of a pipeline of potential vaccines and treatments targeting infectious diseases

EIA required: no

Project included in Carbon Footprint Exercise¹: no

Environmental and Social Assessment

Environmental Assessment

The project concerns investments in research and development activities, carried out by the Promoter and its partners in existing facilities without changing their already authorised scope. An Environmental Impact Assessment (EIA) is therefore not required under EIA Directive 2014/52/EU amending Directive 2011/92/EU.

The promoter maintains adequate internal procedures and management practices that are in line with best industry standards, such as the Good Automated Manufacturing Practice (GAMP5).

Other Environmental and Social Aspects

If successful, the project is expected to lead to important social benefits, as part of the assets under development are addressing the increased incidence of resistant pathogens, which could potentially relieve a significant burden on health services. Moreover, the project will contribute to technological advancements in artificial intelligence (AI) and its applications in healthcare, stemming out of the Promoter's platform for drug discovery.

¹ Only projects that meet the scope of the Pilot Exercise, as defined in the EIB draft Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20,000 tons CO2e/year absolute (gross) or 20,000 tons CO2e/year relative (net) – both increases and savings.

Luxembourg, 30/06/2020

Conclusions and Recommendations

Considering the above, the project is deemed acceptable for the Bank's financing under environmental and social terms.